Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
Open accessThe DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
The presence of tumor-infiltrating T cells is associated with favorable patient outcomes, yet most pancreatic cancers are immunologically silent and resistant to currently available immunotherapies. Here we show using a syngeneic orthotopic implantation model of pancreatic cancer that Pik3ca regulates tumor immunogenicity. Genetic silencing of Pik3ca in KrasG12D/Trp53R172H-driven pancreatic tumors resulted in infiltration of T cells, complete tumor regression, and 100% survival of immunocompetent host mice. By contrast, Pik3ca-null tumors implanted in T cell-deficient mice progressed and killed all of the animals. Adoptive transfer of tumor antigen-experienced T cells eliminated Pik3ca-null tumors in immunodeficient mice. Loss of PIK3CA or inhibition of its effector, AKT, increased the expression of MHC Class I and CD80 on tumor cells. These changes contributed to the increased susceptibility of Pik3ca-null tumors to T cell surveillance. Our results indicate that tumor cell PIK3CA-AKT signaling limits T cell recognition and clearance of pancreatic cancer cells. Strategies that target this pathway may yield an effective immunotherapy for this cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PI3K and AKT1 inhibitors have also been shown to boost IFNG-driven class I and class II antigen presentation as a mechanism of cancer-cell-dependent immunostimulation (Chandrasekaran et al., 2019; Marijt et al., 2019; Sivaram et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sivaram et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635 · cited 1×
“CD4+ T cells may also acquire cytotoxic activity in vivo as seen in some melanomas (47, 48), and can play a role in generating and maintaining memory CD8+ T cells (49, 50).”
BackgroundRequirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Cited by
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“Sivaram et al. have shown an inverse relationship between the PI3K/AKT pathway and MHCI expression in pancreatic cancer, leading to immune evasion [71].”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Hazini, A., Fisher, K., & Seymour, L. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002899 · Cited by 203
KRAS drives immune evasion in a genetic model of pancreatic cancer
Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 191
Self-citationTargeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Qi, Z., Xu, Z., Zhang, L., Zou, Y., Li, J., Yan, W., Li, C., Liu, N., & Wu, H. (2022) · Nature Communications · doi:10.1038/s41467-021-27833-0 · Cited by 137
Zhang, A. M. Y., Xia, Y. H., Lin, J. S. H., Chu, K., Wang, W. C. K., Ruiter, T. J. J., Yang, J. C. C., Chen, N., Chhuor, J., Patil, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.003 · Cited by 113
Sun, P., Zhang, X., Wang, R.-J., Ma, Q., Xu, L., Wang, Y., Liao, H., Wang, H.-L., Hu, L., Kong, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003093 · Cited by 100
Modeling pancreatic cancer in mice for experimental therapeutics
Mallya, K. B., Gautam, S. K., Aithal, A., Batra, S. K., & Jain, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188554 · Cited by 97
Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer
Biancur, D. E., Kapner, K. S., Yamamoto, K., Banh, R. S., Neggers, J. E., Sohn, A. S. W., Wu, W., Manguso, R. T., Brown, A., Root, D. E., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.018 · Cited by 93
Persson, M. L., Douglas, A. M., Alvaro, F., Faridi, P., Larsen, M. R., Alonso, M. M., Vitanza, N. A., & Dun, M. D. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac117 · Cited by 89
Sharma, P., Abramson, V. G., O’Dea, A. P., Nye, L. E., Mayer, I. A., Pathak, H. B., Hoffmann, M. S., Stecklein, S. R., Elia, M., Lewis, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4879 · Cited by 86
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity
Sun, P., & Meng, L. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00500-8 · Cited by 81
Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited – Exploring the “Space”
Bräutigam, K., Skok, K., Szymoński, K., Rift, C. V., & Karamitopoulou, E. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217699 · Cited by 66
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23179 · Cited by 63
Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression
Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0545 · Cited by 61
“Along these lines, in the study by Sivaram and colleagues, the authors found that antitumor immunity against pancreatic tumors lacking PIK3CA required CD4þ T cells (in addition to CD8þ T cells), further implicating potential roles for tumor cell MHCII expression (49).”
MethodResultChen, Y., Wang, Z., Jin, Y., Zhao, Q., Liu, Z., Zuo, Z., Ju, H., Cui, C., Yao, J., Zhang, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.016 · Cited by 60
Judge, S. M., Deyhle, M. R., Neyroud, D., Nosacka, R. L., D’Lugos, A. C., Cameron, M. E., Vohra, R., Smuder, A. J., Roberts, B. M., Callaway, C. S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1558 · Cited by 57
Immunogenomic cancer evolution: A framework to understand cancer immunosuppression
Kumagai, S., Momoi, Y., & Nishikawa, H. (2025) · Science Immunology · doi:10.1126/sciimmunol.abo5570 · Cited by 53
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
Thibault, B., Ramos‐Delgado, F., Pons‐Tostivint, E., Therville, N., Cintas, C., Arcucci, S., Cassant‐Sourdy, S., Reyes‐Castellanos, G., Tosolini, M., Villard, A. V., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013502 · Cited by 44
Zheng, X. F. S., Chen, J., Deng, M., Ning, K., Peng, Y., Liu, Z., Li, X., Zhou, Z., Tang, H., Li, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202305922 · Cited by 46
Neyroud, D., Laitano, O., Dasgupta, A., Lopez, C., Schmitt, R. E., Schneider, J. Z., Hammers, D. W., Sweeney, H. L., Walter, G. A., Doles, J. D., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04902-2 · Cited by 45
Heller, S. R., Glaeske, S., Gluske, K., Paul, J., Böhme, A., Janzer, A., Roider, H. G., Montebaur, A., Nicke, B., Lesche, R., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01227-6 · Cited by 43
Zhang, Q., Xiu, B., Zhang, L.-Y., Chen, M., Chi, W., Li, L., Guo, R., Xue, J., Yang, B., Huang, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004666 · Cited by 37
Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 36
Gu, M., Gao, Y., & Chang, P. (2021) · Cancers · doi:10.3390/cancers13102429 · Cited by 35
“In concert with the KRAS mutation, alterations in environmental, genetic and molecular levels, such as hypoxia, LKB1 mutation, PTEN loss, PIK3CA activation, WNT/β-catenin activation, FAK activation and MYC proto-oncogene (MYC) activation also contribute to immune suppression in PDAC tumors [29,30] (Figure 1).”
BackgroundSubtyping for pancreatic cancer precision therapy
Huang, X., Zhang, G., & Liang, T. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.005 · Cited by 33
The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets
Roberto, M., Arrivi, G., Civita, M. A. D., Barchiesi, G., Pilozzi, E., Marchetti, P., Santini, D., Mazzuca, F., & Tomao, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1154581 · Cited by 26
Yi, Q., Wang, J., Liu, T., Yao, Y., Loveless, I. M., Subedi, K., Toor, J. S., Adrianto, I., Xiao, H. F., Chen, B., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216149 · Cited by 25
Bioengineering Approaches for the Pancreatic Tumor Organoids Research and Application
Song, T., Kong, B., Liu, R., Luo, Y., Wang, Y., & Zhao, Y. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300984 · Cited by 24
Neyroud, D., D’Lugos, A. C., Trevino, E. J., Callaway, C. S., Lamm, J. H., Laitano, O., Poole, B., Deyhle, M. R., Brantley, J., Le, L., et al. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13668 · Cited by 22
Arcucci, S., Ramos‐Delgado, F., Cayron, C., Therville, N., Gratacap, M., Basset, C., Thibault, B., & Guillermet‐Guibert, J. (2021) · Biochemical Journal · doi:10.1042/bcj20210004 · Cited by 21
PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma
Choi, S., Kim, H., Heo, Y. J., Kang, S. Y., Ahn, S., Lee, J., & Kim, K. (2023) · The Journal of Pathology · doi:10.1002/path.6134 · Cited by 20
Ma, N., Hua, R., Yang, Y., Liu, Z., Pan, J., Yu, B., Sun, Y., Xie, D., Wang, Y., & Li, Z. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00912-8 · Cited by 18
Huang, L., Yang, H., Chen, K., Yuan, J., Li, J., Dai, G., Gu, M., & Shi, Y. X. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1500 · Cited by 18
Perales-Linares, R. F., Leli, N. M., Mohei, H., Beghi, S., Rivera, O. D., Κωστόπουλος, Ν., Giglio, A., George, S. S., Uribe‐Herranz, M., Costabile, F., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2499 · Cited by 16
Sun, B., Wang, Y., Sun, J., Zhang, C., Xia, R., Xu, S., Sun, S., & Li, J. (2021) · American Journal of Cancer Research · Cited by 15
Jiang, D., Yuan, X., Ni, J., Shen, L., Cai, M., & Xu, L. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8882129 · Cited by 15
Pancreatic cancer subtyping - the keystone of precision treatment
Fan, Z., Xiao, Y., Du, Y., Zhang, Y., & Zhou, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563725 · Cited by 14
Targeting oncogenic signal pathway to improve cancer immunotherapy: Insights and perspectives
Yang, Q., Sun, H., & Sun, Z. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117043 · Cited by 12
Solomon, P. E., Kirkemo, L. L., Wilson, G. M., Leung, K., Almond, M. H., Sayles, L. C., Sweet-Cordero, A., Rosenberg, O. S., Coon, J. J., & Wells, J. A. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100247 · Cited by 12
Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
Yan, D. (2023) · Biomedicines · doi:10.3390/biomedicines11112916 · Cited by 12
Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC
Zhu, P., Li, Z., Sun, Y., Liu, T., & Yin, R. H. (2024) · Cancer Science · doi:10.1111/cas.16428 · Cited by 11
Sun, R., Chen, T., Li, M., Liu, Z., Qiu, B., Li, Z., Xu, Y., Pan, C., & Zhang, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109583 · Cited by 11
Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model
Han, H. V., Efem, R., Rosati, B., Lu, K., Maimouni, S., Jiang, Y., Montoya, V., Velden, A. W. M. V. D., Zong, W., & Lin, R. Z. (2024) · eLife · doi:10.7554/elife.96925.2 · Cited by 10
Self-citationDown-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors
Chen, C., Jiang, Y., You, I., Gray, N. S., & Lin, R. Z. (2024) · Cells · doi:10.3390/cells13121061 · Cited by 10
Self-citationWondergem, N. E., Nijenhuis, D. N. L. M., Poell, J. B., Leemans, C. R., Brakenhoff, R. H., & van de Ven, R. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.647980 · Cited by 10
Wang, X., Li, L., Yang, Y., Fan, L., Ma, Y., & Mao, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.832715 · Cited by 10
Pancreatic cancer: genetics, disease progression, therapeutic resistance and treatment strategies
Singh, K., Shishodia, G., & Koul, H. K. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.96 · Cited by 10
Cancer-induced FOXP1 disrupts and reprograms skeletal-muscle circadian transcription in cachexia
Ducharme, J. B., Neyroud, D., Schonk, M. M., Gutierrez‐Monreal, M. A., Huo, Z., Tucker, H. O., Esser, K. A., Judge, S. M., & Judge, A. R. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115689 · Cited by 9
Principe, D. R., Becker, J. H., Metropulos, A. E., Marinelarena, A. M., Pham, T. D., Aissa, A. F., & Munshi, H. G. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0483 · Cited by 10
Peng, K., Liu, Y., Liu, S., Wang, Z., Zhang, H., He, W., Jin, Y., Wang, L., Xia, X., & Xia, L. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00916-y · Cited by 9
Zhou, Q., Chen, D., Zhang, J., Xiang, J.-F., Zhang, T., Wang, H., & Zhang, Y. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000109 · Cited by 9
Sankarasubramanian, S., Pfohl, U., Regenbrecht, C. R. A., Reinhard, C., & Wedeken, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760705 · Cited by 7
GETgene-AI: a framework for prioritizing actionable cancer drug targets
Gu, A., & Chen, J. Y. (2025) · Frontiers in Systems Biology · doi:10.3389/fsysb.2025.1649758 · Cited by 6
Köse, H., Schneeweis, C., Putze, P., Contreras, C. T., Ferreiro, L., Witte, L., Deidda, I., Herzberg, F., Ebert, S., Jakubík, J., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.018 · Cited by 6
Enzyme-Free Colorimetric Method for Fast Detection of PIK3CA Gene Mutation by Praseodymia Nanorods
Jiang, L., Wang, M., Li, Y., Zhang, S., Zhu, X., Zhong, J., Sun, J., Tinoco, M., & Chen, X. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04419 · Cited by 6
Rare germline variants in pancreatic cancer and multiple primary cancers: an autopsy study
Fujitani, H., Eguchi, H., Kochi, Y., Arai, T., Muramatsu, M., & Okazaki, Y. (2023) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000787 · Cited by 6
Tada, H., Nagata, Y., Takahashi, H., Matsuyama, T., Ida, S., Mito, I., & Chikamatsu, K. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2309 · Cited by 5
Ducharme, J. B., Ebert, S. M., Cameron, M. E., Schonk, M. M., Callaway, C. S., D’Lugos, A. C., Talley, J. J., Judge, S. M., Adams, C. M., & Judge, A. R. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00159.2026 · Cited by 4
Zhang, D., Wan, C., Chen, C., Li, Q., Mengke, L., Dou, M., Jiawei, Y., Longxi, Q., Liu, H., Liu, J., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11949-9 · Cited by 4
Gu, C., He, R., Yin, X., Wang, J., Yang, J., Gao, J., Xie, R., Geng, Y., Lu, J., Ke, Z., et al. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01222-5 · Cited by 3
Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma
Bao, J., Xu, C., Li, B., Wu, Z., Shen, J., Song, P., Peng, Q., & Hu, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834728 · Cited by 2
Huang, H., Zhou, S., Zhao, X., Wang, S., Yu, H., Lan, L., & Li, L. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12378 · Cited by 2
Data‐Driven Molecular Typing: A New Frontier in Esophageal Cancer Management
Du, Y., Gu, B., Shi, L., She, Y., Zhao, Q., & Gao, S. (2025) · Cancer Medicine · doi:10.1002/cam4.70730 · Cited by 1
Gaikwad, S. R., & Srivastava, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.029 · Cited by 1
Hu, C., Yin, Y., Xu, D., Xu, Y., Yang, J., Xu, Y.-N., & Hua, R. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01533-7 · Cited by 1
Park, J. C., Basak, N. P., Useche, M., Park, J. S., Ganesh, M. S., Prabha, A. G., JayaPrakash, C. R., Varvares, M. A., Wirth, L. J., Faquin, W. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.02.601738 · Cited by 1
Ma, N., Hua, R., Yang, Y., Liu, Z., Pan, J., Yu, B., Sun, Y., Xie, D., Wang, Y., & Li, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22621634
Ma, N., Hua, R., Yang, Y., Liu, Z., Pan, J., Yu, B., Sun, Y., Xie, D., Wang, Y., & Li, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22621643
Ma, N., Hua, R., Yang, Y., Liu, Z., Pan, J., Yu, B., Sun, Y., Xie, D., Wang, Y., & Li, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22621637
Ma, N., Hua, R., Yang, Y., Liu, Z., Pan, J., Yu, B., Sun, Y., Xie, D., Wang, Y., & Li, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22621640
Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse modelPreprint
Han, H. V., Efem, R., Rosati, B., Lu, K., Maimouni, S., Jiang, Y., Montoya, V., van der Velden, A. W. M., Zong, W., & Lin, R. Z. (2024) · eLife · doi:10.7554/elife.96925.1
Self-citationHan, H. V., Efem, R., Rosati, B., Lu, K., Maimouni, S., Jiang, Y., Montoya, V., van der Velden, A. W. M., Zong, W., & Lin, R. Z. (2024) · eLife · doi:10.7554/elife.96925.1.sa4
Self-citationSaladi, S. V., Park, J. C., Basak, N. P., Useche, M., Park, J. S., Ganesh, M., Prabha, A. G., JayaPrakash, C. R., Varvares, M. A., Wirth, L. J., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5237193
Mammalian Neuraminidase-1 is a Critical Target of Thromboxane Induced T-Cell ImmunosuppressionPreprint
Harless, W. W., Li, Y., & Szewczuk, M. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.01.691391
Dong, Z., Chong, W., Chen, C., Qi, L., Mengke, L., Dou, M., Jiawei, Y., Longxi, Q., Liu, H., Liu, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26688293
Ma, N., Hua, R., Yang, Y., Liu, Z.-C., Pan, J., Yu, B., Sun, Y.-F., Xie, D., Wang, Y., & Li, Z.-G. (2023) · Figshare · doi:10.6084/m9.figshare.22621631
Booth, A., Caso, G., Rosati, B., Jiang, Y.-P., zong, W.-X., Lin, R. Z., & Bien, H. (2026) · Cells · doi:10.3390/cells15060506
Self-citationExploring PI3K signalling dynamics in pancreatic cancer
Delgado, C. F. R. (2020) · theses.fr (ABES) · doi:10.70675/6df9a059zc3f1z4997z9de2z34a1d24dfbeb
Characterizing and targeting the microenviromental changes in PIK3CA related overgrowth syndromes
Galasso, I. (2024) · theses.fr (ABES) · doi:10.70675/b81c167azcc23z4977z90f0z0ff71e3da7c4
Complement C1q drives skeletal muscle wasting in pancreatic cancerPreprint
Judge, A. R., Ducharme, J. B., Schonk, M. M., Poole, B., Al-Zaeed, N., Duckett, S., Vogt, R., Binienda, T., Park, M., Permuth, J. B., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11516792/v1
Bao, J., Xu, C., Li, B., Wu, Z., Shen, J., Song, P., Peng, Q., & Hu, G. (2022) · doi:10.3389/fonc.2022.834728.s005
Metadata
- Authors
- Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z.
- Affiliations
- Stony Brook University (US)
- Rutgers, The State University of New Jersey (US)
- Northport VA Medical Center (US)
- Corresponding author
- Lin, Richard Z.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-07-15
- Volume
- 129
- Issue
- 8
- Pages
- 3264-3276
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6668699
- OpenAlex
- W2945115405
- Cited by
- 78
- References
- 71
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 11 · 2023: 18 · 2022: 10 · 2021: 15 · 2020: 7 · 2019: 2
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (BX004083)
- National Cancer Institute (CA194836)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK108989)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- PIK3CA, Akt signaling, pancreatic cancer, tumor immunogenicity, tumor-infiltrating T cells, KRAS G12D, MHC class I expression, CD80, T cell surveillance, adoptive T cell therapy, cancer immunotherapy, tumor immunosuppression
- MeSH terms
- Animals, Humans, Neoplasms, Experimental, Pancreatic Neoplasms, T-Lymphocytes, Histocompatibility Antigens Class I, Signal Transduction, Lymphocytes, Tumor-Infiltrating, Mice, SCID, B7-1 Antigen, Mice, Knockout, Adoptive Transfer, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Mice, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.